A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage.
Ladds, M.J.G.W., van Leeuwen, I.M.M., Drummond, C.J., Chu, S., Healy, A.R., Popova, G., Pastor Fernandez, A., Mollick, T., Darekar, S., Sedimbi, S.K., Nekulova, M., Sachweh, M.C.C., Campbell, J., Higgins, M., Tuck, C., Popa, M., Safont, M.M., Gelebart, P., Fandalyuk, Z., Thompson, A.M., Svensson, R., Gustavsson, A.L., Johansson, L., Farnegardh, K., Yngve, U., Saleh, A., Haraldsson, M., D'Hollander, A.C.A., Franco, M., Zhao, Y., Hakansson, M., Walse, B., Larsson, K., Peat, E.M., Pelechano, V., Lunec, J., Vojtesek, B., Carmena, M., Earnshaw, W.C., McCarthy, A.R., Westwood, N.J., Arsenian-Henriksson, M., Lane, D.P., Bhatia, R., McCormack, E., Lain, S.(2018) Nat Commun 9: 1107-1107
- PubMed: 29549331 
- DOI: https://doi.org/10.1038/s41467-018-03441-3
- Primary Citation of Related Structures:  
6ET4 - PubMed Abstract: 
The development of non-genotoxic therapies that activate wild-type p53 in tumors is of great interest since the discovery of p53 as a tumor suppressor. Here we report the identification of over 100 small-molecules activating p53 in cells. We elucidate the mechanism of action of a chiral tetrahydroindazole (HZ00), and through target deconvolution, we deduce that its active enantiomer (R)-HZ00, inhibits dihydroorotate dehydrogenase (DHODH) ...